Back to the complete issue
Monday, 12 July 2021

More than 2.25 mn vaccines will be delivered this week

Pfizer, AstraZeneca, J&J jabs to arrive this week: Egypt will receive our first 2 mn-dose shipment of the Pfizer / BioNTech mRNA vaccine by the end of this week while a new 250k-jab batch of the Oxford / AstraZeneca vaccine is due as soon as mid-week, the Health Ministry’s spokesperson Khaled Megahed told Kelma Akhira’s Lamees El Hadidi last night (watch, runtime 2:57), elaborating on statements made by Health Minister Hala Zayed last week. The AstraZeneca shots could be part of the final 1.9 mn-dose batch allocated under the Gavi / Covax program that Zayed previously said would arrive in July.

The first shipment of Johnson & Johnson vaccines will also arrive this week, Megahed said, without specifying an amount.

State-owned vaccine maker Vacsera will produce another 1 mn Sinovac shots in the coming days, Megahed noted. We’ll receive raw materials that will be enough to produce another 3 mn doses by the end of this week, before receiving another shipment to manufacture an additional 4.7 mn a week later. The company manufactured 1 mn doses of the vaccine earlier this month and is targeting 10 mn by the end of July and 80 mn by the end of the year.

Home-made Sinovac will be available in clinics in mid-August, Vacsera head Heba Wali reiterated in an interview for Ala Mas’ouleety (watch, runtime 7:36). This contradicts information given by a health ministry advisor last week, who said that the first shots could be sent out in the coming two weeks.

The Health Ministry reported 117 new covid-19 infections yesterday, down from 121 the day before. Egypt has now disclosed a total of 283,102 confirmed cases of covid-19. The ministry also reported 13 new deaths, bringing the country’s total death toll to 16,396.

Enterprise is a daily publication of Enterprise Ventures LLC, an Egyptian limited liability company (commercial register 83594), and a subsidiary of Inktank Communications. Summaries are intended for guidance only and are provided on an as-is basis; kindly refer to the source article in its original language prior to undertaking any action. Neither Enterprise Ventures nor its staff assume any responsibility or liability for the accuracy of the information contained in this publication, whether in the form of summaries or analysis. © 2021 Enterprise Ventures LLC.